Coherus: Ophthalmologists Have Been ‘Burned Time And Again’
Firm ‘Pleased And Confident’ With ‘Non-Core’ Lucentis Biosimilar, Cimerli
Coherus BioSciences revealed that it has shipped nearly 200,000 doses of its Lucentis biosimilar Cimerli, as it pondered from where to grab further market share in 2024 at the J.P. Morgan Annual Healthcare Conference.
